TY - JOUR AU - Kirby, M. AU - Hirst, C. AU - Crawford, E. D. PY - 2011 DA - 2011// TI - Characterising the castration-resistant prostate cancer population: a systematic review JO - Int J Clin Pract VL - 65 UR - https://doi.org/10.1111/j.1742-1241.2011.02799.x DO - 10.1111/j.1742-1241.2011.02799.x ID - Kirby2011 ER - TY - JOUR AU - Wright, G. L. AU - Haley, C. AU - Beckett, M. L. AU - Schellhammer, P. F. PY - 1995 DA - 1995// TI - Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues JO - Urol Oncol VL - 1 UR - https://doi.org/10.1016/1078-1439(95)00002-Y DO - 10.1016/1078-1439(95)00002-Y ID - Wright1995 ER - TY - JOUR AU - Rybalov, M. AU - Ananias, H. J. AU - Hoving, H. D. AU - van der Poel, H. G. AU - Rosati, S. AU - de Jong, I. J. PY - 2014 DA - 2014// TI - PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy JO - Int J Mol Sci VL - 15 UR - https://doi.org/10.3390/ijms15046046 DO - 10.3390/ijms15046046 ID - Rybalov2014 ER - TY - JOUR AU - Minner, S. AU - Wittmer, C. AU - Graefen, M. AU - Salomon, G. AU - Steuber, T. AU - Haese, A. PY - 2011 DA - 2011// TI - High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer JO - Prostate VL - 71 UR - https://doi.org/10.1002/pros.21241 DO - 10.1002/pros.21241 ID - Minner2011 ER - TY - JOUR AU - Lutje, S. AU - Heskamp, S. AU - Cornelissen, A. S. AU - Poeppel, T. D. AU - van den Broek, S. A. AU - Rosenbaum-Krumme, S. PY - 2015 DA - 2015// TI - PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status JO - Theranostics VL - 5 UR - https://doi.org/10.7150/thno.13348 DO - 10.7150/thno.13348 ID - Lutje2015 ER - TY - JOUR AU - Israeli, R. S. AU - Powell, C. T. AU - Corr, J. G. AU - Fair, W. R. AU - Heston, W. D. PY - 1994 DA - 1994// TI - Expression of the prostate-specific membrane antigen JO - Cancer Res VL - 54 ID - Israeli1994 ER - TY - JOUR AU - Carter, R. E. AU - Feldman, A. R. AU - Coyle, J. T. PY - 1996 DA - 1996// TI - Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase JO - Proc Natl Acad Sci U S A VL - 93 UR - https://doi.org/10.1073/pnas.93.2.749 DO - 10.1073/pnas.93.2.749 ID - Carter1996 ER - TY - JOUR AU - Eder, M. AU - Schafer, M. AU - Bauder-Wust, U. AU - Hull, W. E. AU - Wangler, C. AU - Mier, W. PY - 2012 DA - 2012// TI - 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging JO - Bioconjug Chem VL - 23 UR - https://doi.org/10.1021/bc200279b DO - 10.1021/bc200279b ID - Eder2012 ER - TY - JOUR AU - Benesova, M. AU - Schafer, M. AU - Bauder-Wust, U. AU - Afshar-Oromieh, A. AU - Kratochwil, C. AU - Mier, W. PY - 2015 DA - 2015// TI - Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer JO - J Nucl Med VL - 56 UR - https://doi.org/10.2967/jnumed.114.147413 DO - 10.2967/jnumed.114.147413 ID - Benesova2015 ER - TY - JOUR AU - Rahbar, K. AU - Ahmadzadehfar, H. AU - Kratochwil, C. AU - Haberkorn, U. AU - Schafers, M. AU - Essler, M. PY - 2017 DA - 2017// TI - German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients JO - J Nucl Med VL - 58 UR - https://doi.org/10.2967/jnumed.116.183194 DO - 10.2967/jnumed.116.183194 ID - Rahbar2017 ER - TY - JOUR AU - Kulkarni, H. R. AU - Singh, A. AU - Schuchardt, C. AU - Niepsch, K. AU - Sayeg, M. AU - Leshch, Y. PY - 2016 DA - 2016// TI - PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013 JO - J Nucl Med VL - 57 UR - https://doi.org/10.2967/jnumed.115.170167 DO - 10.2967/jnumed.115.170167 ID - Kulkarni2016 ER - TY - JOUR AU - Ahmadzadehfar, H. AU - Rahbar, K. AU - Kurpig, S. AU - Bogemann, M. AU - Claesener, M. AU - Eppard, E. PY - 2015 DA - 2015// TI - Early side effects and first results of radioligand therapy with (177) Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study JO - EJNMMI Res VL - 5 ID - Ahmadzadehfar2015 ER - TY - JOUR AU - Ahmadzadehfar, H. AU - Eppard, E. AU - Kurpig, S. AU - Fimmers, R. AU - Yordanova, A. AU - Schlenkhoff, C. D. PY - 2016 DA - 2016// TI - Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.7245 DO - 10.18632/oncotarget.7245 ID - Ahmadzadehfar2016 ER - TY - JOUR AU - Schlenkhoff, C. D. AU - Knupfer, E. AU - Essler, M. AU - Ahmadzadehfar, H. PY - 2016 DA - 2016// TI - Metastatic prostate cancer with restored hormone-response after radioligand therapy with 177Lu-PSMA-617 JO - Clin Nucl Med VL - 41 UR - https://doi.org/10.1097/RLU.0000000000001200 DO - 10.1097/RLU.0000000000001200 ID - Schlenkhoff2016 ER - TY - JOUR AU - Kratochwil, C. AU - Giesel, F. L. AU - Eder, M. AU - Afshar-Oromieh, A. AU - Benesova, M. AU - Mier, W. PY - 2015 DA - 2015// TI - [(177) Lu] lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer JO - Eur J Nucl Med Mol Imaging VL - 42 UR - https://doi.org/10.1007/s00259-014-2978-1 DO - 10.1007/s00259-014-2978-1 ID - Kratochwil2015 ER - TY - STD TI - Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, et al. Repeated Lu-177-PSMA-617 radioligand therapy using treatment activities up to 9.3 GBq. J Nucl Med. 2017;59(3):459-465. ID - ref16 ER - TY - JOUR AU - Delker, A. AU - Fendler, W. P. AU - Kratochwil, C. AU - Brunegraf, A. AU - Gosewisch, A. AU - Gildehaus, F. J. PY - 2016 DA - 2016// TI - Dosimetry for (177) Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer JO - Eur J Nucl Med Mol Imaging VL - 43 UR - https://doi.org/10.1007/s00259-015-3174-7 DO - 10.1007/s00259-015-3174-7 ID - Delker2016 ER - TY - JOUR AU - Fendler, W. P. AU - Kratochwil, C. AU - Ahmadzadehfar, H. AU - Rahbar, K. AU - Baum, R. P. AU - Schmidt, M. PY - 2016 DA - 2016// TI - 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer JO - Nuklearmedizin VL - 55 ID - Fendler2016 ER - TY - JOUR AU - Rahbar, K. AU - Schmidt, M. AU - Heinzel, A. AU - Eppard, E. AU - Bode, A. AU - Yordanova, A. PY - 2016 DA - 2016// TI - Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis JO - J Nucl Med VL - 57 UR - https://doi.org/10.2967/jnumed.116.173757 DO - 10.2967/jnumed.116.173757 ID - Rahbar2016 ER - TY - JOUR AU - Rahbar, K. AU - Bode, A. AU - Weckesser, M. AU - Avramovic, N. AU - Claesener, M. AU - Stegger, L. PY - 2016 DA - 2016// TI - Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer JO - Clin Nucl Med VL - 41 UR - https://doi.org/10.1097/RLU.0000000000001240 DO - 10.1097/RLU.0000000000001240 ID - Rahbar2016 ER - TY - JOUR AU - Rahbar, K. AU - Boegemann, M. AU - Yordanova, A. AU - Eveslage, M. AU - Schafers, M. AU - Essler, M. PY - 2018 DA - 2018// TI - PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival JO - Eur J Nucl Med Mol Imaging VL - 45 UR - https://doi.org/10.1007/s00259-017-3848-4 DO - 10.1007/s00259-017-3848-4 ID - Rahbar2018 ER - TY - JOUR AU - Brauer, A. AU - Grubert, L. S. AU - Roll, W. AU - Schrader, A. J. AU - Schafers, M. AU - Bogemann, M. PY - 2017 DA - 2017// TI - (177) Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3751-z DO - 10.1007/s00259-017-3751-z ID - Brauer2017 ER - TY - JOUR AU - Ahmadzadehfar, H. AU - Wegen, S. AU - Yordanova, A. AU - Fimmers, R. AU - Kurpig, S. AU - Eppard, E. PY - 2017 DA - 2017// TI - Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177) Lu] Lu-PSMA-617 JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3716-2 DO - 10.1007/s00259-017-3716-2 ID - Ahmadzadehfar2017 ER - TY - JOUR AU - Sjögreen Gleisner, K. AU - Spezi, E. AU - Solny, P. AU - Gabina, P. M. AU - Cicone, F. AU - Stokke, C. PY - 2017 DA - 2017// TI - Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey JO - EJNMMI Physics VL - 4 UR - https://doi.org/10.1186/s40658-017-0193-4 DO - 10.1186/s40658-017-0193-4 ID - Sjögreen Gleisner2017 ER - TY - BOOK PY - 2001 DA - 2001// TI - Ordinance on the protection against damage and injuries caused by ionizing radiation (radiation protection ordinance) [Strahlenschutzverordnung] ID - ref25 ER - TY - JOUR AU - Fraenkel, M. AU - Kim, M. AU - Faggiano, A. AU - de Herder, W. W. AU - Valk, G. D. AU - Knowledge, N. PY - 2014 DA - 2014// TI - Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature JO - Endocr Relat Cancer VL - 21 UR - https://doi.org/10.1530/ERC-13-0125 DO - 10.1530/ERC-13-0125 ID - Fraenkel2014 ER - TY - JOUR AU - Yao, J. C. AU - Hassan, M. AU - Phan, A. AU - Dagohoy, C. AU - Leary, C. AU - Mares, J. E. PY - 2008 DA - 2008// TI - One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.4377 DO - 10.1200/JCO.2007.15.4377 ID - Yao2008 ER - TY - BOOK PY - 2012 DA - 2012// TI - European Cancer Observatory (ECO) ID - ref28 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21254 DO - 10.3322/caac.21254 ID - Siegel2015 ER - TY - JOUR PY - 2015 DA - 2015// TI - Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances JO - Ann ICRP VL - 44 ID - ref30 ER - TY - JOUR PY - 2007 DA - 2007// TI - The 2007 recommendations of the international commission on radiological protection. ICRP publication 103 JO - Ann ICRP VL - 37 ID - ref31 ER - TY - CHAP PY - 2014 DA - 2014// TI - Council Directive 2013/59/Euratom of 5 December 2013 BT - Off J Eur Union ID - ref32 ER - TY - JOUR AU - Demir, M. AU - Abuqbeitah, M. AU - Uslu-Besli, L. AU - Yildirim, O. AU - Yeyin, N. AU - Cavdar, I. PY - 2016 DA - 2016// TI - Evaluation of radiation safety in (177) Lu-PSMA therapy and development of outpatient treatment protocol JO - J Radiol Prot VL - 36 UR - https://doi.org/10.1088/0952-4746/36/2/269 DO - 10.1088/0952-4746/36/2/269 ID - Demir2016 ER - TY - BOOK PY - 2014 DA - 2014// TI - Directive on radiation protection in medicine [Richtlinie Strahlenschutz in der Medizin] ID - ref34 ER - TY - STD TI - German Commission on Radiological Protection [Strahlenschutzkommission - SSK]. Radiation protection principles for radioiodine therapy. Berlin; 1998. https://www.ssk.de/SharedDocs/Beratungsergebnisse_PDF/1996/1996_13e.pdf?__blob=publicationFile. Accessed 26 Oct 2017 UR - https://www.ssk.de/SharedDocs/Beratungsergebnisse_PDF/1996/1996_13e.pdf?__blob=publicationFile ID - ref35 ER - TY - JOUR AU - Fitschen, J. AU - Knoop, B. O. AU - Behrendt, R. AU - Knapp, W. H. AU - Geworski, L. PY - 2011 DA - 2011// TI - External radiation exposure and effective half-life in Lu-177-Dota-Tate therapy JO - Z Med Phys VL - 21 UR - https://doi.org/10.1016/j.zemedi.2011.05.001 DO - 10.1016/j.zemedi.2011.05.001 ID - Fitschen2011 ER - TY - JOUR AU - Kossert, K. AU - Nahle, O. J. AU - Ott, O. AU - Dersch, R. PY - 2012 DA - 2012// TI - Activity determination and nuclear decay data of 177Lu JO - Appl Radiat Isot VL - 70 UR - https://doi.org/10.1016/j.apradiso.2012.02.104 DO - 10.1016/j.apradiso.2012.02.104 ID - Kossert2012 ER - TY - JOUR AU - Siegel, J. A. AU - Thomas, S. R. AU - Stubbs, J. B. AU - Stabin, M. G. AU - Hays, M. T. AU - Koral, K. F. PY - 1999 DA - 1999// TI - MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates JO - J Nucl Med VL - 40 ID - Siegel1999 ER - TY - JOUR AU - Buckley, S. E. AU - Saran, F. H. AU - Gaze, M. N. AU - Chittenden, S. AU - Partridge, M. AU - Lancaster, D. PY - 2007 DA - 2007// TI - Dosimetry for fractionated (131) I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results JO - Cancer Biother Radiopharm VL - 22 UR - https://doi.org/10.1089/cbr.2007.301 DO - 10.1089/cbr.2007.301 ID - Buckley2007 ER - TY - JOUR AU - Chittenden, S. J. AU - Pratt, B. E. AU - Pomeroy, K. AU - Black, P. AU - Long, C. AU - Smith, N. PY - 2007 DA - 2007// TI - Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy JO - Cancer Biother Radiopharm VL - 22 UR - https://doi.org/10.1089/cbr.2006.315 DO - 10.1089/cbr.2006.315 ID - Chittenden2007 ER - TY - JOUR AU - Hindorf, C. AU - Glatting, G. AU - Chiesa, C. AU - Linden, O. AU - Flux, G. PY - 2010 DA - 2010// TI - EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry JO - Eur J Nucl Med Mol Imaging VL - 37 UR - https://doi.org/10.1007/s00259-010-1422-4 DO - 10.1007/s00259-010-1422-4 ID - Hindorf2010 ER - TY - JOUR AU - Kletting, P. AU - Kull, T. AU - Reske, S. N. AU - Glatting, G. PY - 2009 DA - 2009// TI - Comparing time activity curves using the Akaike information criterion JO - Phys Med Biol VL - 54 UR - https://doi.org/10.1088/0031-9155/54/21/N01 DO - 10.1088/0031-9155/54/21/N01 ID - Kletting2009 ER - TY - JOUR AU - Kabasakal, L. AU - AbuQbeitah, M. AU - Aygun, A. AU - Yeyin, N. AU - Ocak, M. AU - Demirci, E. PY - 2015 DA - 2015// TI - Pre-therapeutic dosimetry of normal organs and tissues of (177) Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer JO - Eur J Nucl Med Mol Imaging VL - 42 UR - https://doi.org/10.1007/s00259-015-3125-3 DO - 10.1007/s00259-015-3125-3 ID - Kabasakal2015 ER - TY - JOUR AU - Hohberg, M. AU - Eschner, W. AU - Schmidt, M. AU - Dietlein, M. AU - Kobe, C. AU - Fischer, T. PY - 2016 DA - 2016// TI - Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [(177) Lu] DKFZ-PSMA-617 JO - Mol Imaging Biol VL - 18 UR - https://doi.org/10.1007/s11307-016-0942-0 DO - 10.1007/s11307-016-0942-0 ID - Hohberg2016 ER - TY - JOUR AU - Wehrmann, C. AU - Senftleben, S. AU - Zachert, C. AU - Muller, D. AU - Baum, R. P. PY - 2007 DA - 2007// TI - Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC JO - Cancer Biother Radiopharm VL - 22 UR - https://doi.org/10.1089/cbr.2006.325 DO - 10.1089/cbr.2006.325 ID - Wehrmann2007 ER - TY - JOUR AU - Esser, J. P. AU - Krenning, E. P. AU - Teunissen, J. J. AU - Kooij, P. P. AU - van Gameren, A. L. AU - Bakker, W. H. PY - 2006 DA - 2006// TI - Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu-DOTA (0), Tyr (3)] octreotide: which peptide is preferable for PRRT? JO - Eur J Nucl Med Mol Imaging VL - 33 UR - https://doi.org/10.1007/s00259-006-0172-9 DO - 10.1007/s00259-006-0172-9 ID - Esser2006 ER - TY - JOUR AU - Calais, P. J. AU - Turner, J. H. PY - 2014 DA - 2014// TI - Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors JO - Ann Nucl Med VL - 28 UR - https://doi.org/10.1007/s12149-014-0843-8 DO - 10.1007/s12149-014-0843-8 ID - Calais2014 ER - TY - JOUR AU - Liu, B. AU - de Blois, E. AU - Breeman, W. A. AU - Konijnenberg, M. W. AU - Wolterbeek, H. T. AU - Bode, P. PY - 2015 DA - 2015// TI - Accurate assessment of whole-body retention for PRRT with (177) Lu using paired measurements with external detectors JO - Curr Radiopharm VL - 8 UR - https://doi.org/10.2174/1874471008666150313110000 DO - 10.2174/1874471008666150313110000 ID - Liu2015 ER - TY - JOUR AU - Strosberg, J. AU - El-Haddad, G. AU - Wolin, E. AU - Hendifar, A. AU - Yao, J. AU - Chasen, B. PY - 2017 DA - 2017// TI - Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1607427 DO - 10.1056/NEJMoa1607427 ID - Strosberg2017 ER - TY - JOUR AU - Yordanova, A. AU - Mayer, K. AU - Brossart, P. AU - Gonzalez-Carmona, M. A. AU - Strassburg, C. P. AU - Essler, M. PY - 2017 DA - 2017// TI - Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3652-1 DO - 10.1007/s00259-017-3652-1 ID - Yordanova2017 ER - TY - JOUR AU - Horsch, D. AU - Ezziddin, S. AU - Haug, A. AU - Gratz, K. F. AU - Dunkelmann, S. AU - Miederer, M. PY - 2016 DA - 2016// TI - Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up JO - Eur J Cancer VL - 58 UR - https://doi.org/10.1016/j.ejca.2016.01.009 DO - 10.1016/j.ejca.2016.01.009 ID - Horsch2016 ER - TY - JOUR AU - Buck, A. K. AU - Stolzenburg, A. AU - Hanscheid, H. AU - Schirbel, A. AU - Luckerath, K. AU - Schottelius, M. PY - 2017 DA - 2017// TI - Chemokine receptor—directed imaging and therapy JO - Methods VL - 130 UR - https://doi.org/10.1016/j.ymeth.2017.09.002 DO - 10.1016/j.ymeth.2017.09.002 ID - Buck2017 ER - TY - JOUR AU - Dalm, S. U. AU - Schrijver, W. A. AU - Sieuwerts, A. M. AU - Look, M. P. AU - Ziel-van, d. AU - Made, A. C. AU - de Weerd, V. PY - 2017 DA - 2017// TI - Prospects of targeting the gastrin releasing peptide receptor and somatostatin receptor 2 for nuclear imaging and therapy in metastatic breast cancer JO - PLoS One VL - 12 UR - https://doi.org/10.1371/journal.pone.0170536 DO - 10.1371/journal.pone.0170536 ID - Dalm2017 ER - TY - JOUR AU - Maina, T. AU - Nock, B. A. AU - Kulkarni, H. AU - Singh, A. AU - Baum, R. P. PY - 2017 DA - 2017// TI - Theranostic prospects of gastrin-releasing peptide receptor-radioantagonists in oncology JO - PET Clinics VL - 12 UR - https://doi.org/10.1016/j.cpet.2017.02.007 DO - 10.1016/j.cpet.2017.02.007 ID - Maina2017 ER - TY - JOUR AU - Kang, C. S. AU - Chen, Y. AU - Lee, H. AU - Liu, D. AU - Sun, X. AU - Kweon, J. PY - 2015 DA - 2015// TI - Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using (90) Y or (177) Lu JO - Nucl Med Biol VL - 42 UR - https://doi.org/10.1016/j.nucmedbio.2014.10.004 DO - 10.1016/j.nucmedbio.2014.10.004 ID - Kang2015 ER - TY - BOOK PY - 1996 DA - 1996// TI - NCRP report no. 123, screening models for releases of radionuclides to the atmosphere, surface water, and ground ID - ref56 ER -